Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287858 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT01287858 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 88 participants.
The verdict
NCT01287858, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
AC430 will be administered, orally under fasting conditions (fasting 4 hours before and 2 hours after dosing) with approximately 240 mL of water either once daily or twice daily. It is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses of AC430.
Interventions
- DRUG AC430
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287858
The ClinicalTrials.gov registry entry for NCT01287858 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AC430 is the first listed.
NCT01287858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01287858 about?
NCT01287858 is a clinical study titled "Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects". AC430 will be administered, orally under fasting conditions (fasting 4 hours before and 2 hours after dosing) with approximately 240 mL of water either once daily or twice daily. It is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses of AC430.
What is the current status of trial NCT01287858?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2010-11. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01287858?
The interventions under investigation include: AC430 (DRUG).
Who is sponsoring clinical trial NCT01287858?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.